Company research
DR REDDYS LABORATORIES LTD
CIK 1135951Updated Sep 24, 2026
SecurityRDY · NYSE · adr
RDY price & chart
Loading TradingView…
NYSE:RDY on TradingView ↗In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ↗
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | 671,000,000Source | 668,000,000Source | 548,000,000Source | 311,000,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | — | — | — | — |
| Additional Financial Items | ||||
| AdjustmentsForIncomeTaxExpenseUSD | 229,000,000Source | 194,000,000Source | 186,000,000Source | 115,000,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 5,000,000Source | 5,000,000Source | 5,000,000Source | 8,000,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 2,000,000Source | -6,000,000Source | -11,000,000Source | -10,000,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesUSD | 78,000,000Source | 80,000,000Source | 61,000,000Source | 55,000,000Source |
| GoodwillUSD | 138,000,000Source | 51,000,000Source | 52,000,000Source | 58,000,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 41,000,000Source | 27,000,000Source | 23,000,000Source | 18,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesINR | — | — | — | 0Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesINR | 80,646,000,000Source | 19,366,000,000Source | 49,234,000,000Source | 51,518,000,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | 3,273,000,000Source | 1,557,000,000Source | 1,372,000,000Source | 1,025,000,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 6,000,000Source | 13,000,000Source | 1,000,000Source | 5,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 81,000,000Source | 132,000,000Source | 92,000,000Source | 58,000,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesINR | 56,156,000,000Source | 13,873,000,000Source | 68,616,000,000Source | 47,998,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 1,099,000,000Source | 926,000,000Source | 828,000,000Source | 818,000,000Source |
| Total RevenueUSD | 3,811,000,000Source | 3,350,000,000Source | 2,992,000,000Source | 2,826,000,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | — | 0.35Source | 0.35Source |
| AverageEffectiveTaxRatenumber | 0.25Source | 0.23Source | 0.25Source | 0.27Source |
| BasicEarningsLossPerShareUSD per share | 0.79Source | 4.02Source | 3.3Source | 1.87Source |
| CurrentTaxExpenseIncomeINR | 22,581,000,000Source | 19,458,000,000Source | 12,858,000,000Source | 6,411,000,000Source |
| DeferredTaxExpenseIncomeINR | -3,042,000,000Source | -3,272,000,000Source | 2,442,000,000Source | 2,319,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossINR | 3,052,000,000Source | 3,381,000,000Source | -2,018,000,000Source | -2,165,000,000Source |
| DepreciationRightofuseAssetsINR | 1,249,000,000Source | 1,143,000,000Source | 879,000,000Source | 858,000,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.79Source | 4.01Source | 3.3Source | 1.87Source |
| EmployeeBenefitsExpenseINR | 55,800,000,000Source | 50,300,000,000Source | 46,465,000,000Source | 38,858,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesINR | 796,000,000Source | 821,000,000Source | 644,000,000Source | 740,000,000Source |
| FinanceCostsUSD | 33,000,000Source | 21,000,000Source | 17,000,000Source | 13,000,000Source |
| FinanceIncomeUSD | 88,000,000Source | 68,000,000Source | 52,000,000Source | 41,000,000Source |
| GrossProfitUSD | 2,230,000,000Source | 1,963,000,000Source | 1,695,000,000Source | 1,500,000,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | 20,000,000Source | 1,000,000Source | 9,000,000Source | 100,000,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 229,000,000Source | 194,000,000Source | 186,000,000Source | 115,000,000Source |
| InterestExpenseINR | 2,829,000,000Source | 1,711,000,000Source | 1,428,000,000Source | 958,000,000Source |
| InterestExpenseOnLeaseLiabilitiesINR | 391,000,000Source | 256,000,000Source | 214,000,000Source | 221,000,000Source |
| OtherOperatingIncomeExpenseUSD | 51,000,000Source | 50,000,000Source | 72,000,000Source | 36,000,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | 8,000,000Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | 663,000,000Source | — | — | — |
| ProfitLossBeforeTaxUSD | 900,000,000Source | 862,000,000Source | 734,000,000Source | 426,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | 842,000,000Source | 813,000,000Source | 695,000,000Source | 389,000,000Source |
| ResearchAndDevelopmentExpenseUSD | 320,000,000Source | 274,000,000Source | 236,000,000Source | 230,000,000Source |
Filing attachments
rdy0944_ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── September 22, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code:…
Read attachment ↗rdy0943_ex99-1.htm · 6-K · 2026-09-21
EX-99.1 2 rdy0943_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com ───────────────────────────────────────── September 21, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc.…
Read attachment ↗